Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 4 study of Valdoxan in major depressive disorder
2009-010642-57Phase 4Completed
- Sponsor
- Servier
- Start
- Jun 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of agomelatine in major depressive disorder (MDD), sponsored by Servier. Primary endpoint: Change in depressive symptoms by MADRS. Started Jun 2009; status: completed.
02
Drugs
agomelatine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2009-010642-57.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-010642-57.